News Alnylam halts trials of haemophilia drug after patient death Trials will resume once safety protocols have been reviewed.
News Silence Therapeutics takes rival Alnylam to court in patent ... Silence claims late-stage drugs infringe patents.
News Ionis hit by safety concerns, rivals Alnylam benefit Biotech insists drug for rare inherited disorder is still approvable.
News Alnylam plunges after deaths in rare disease trial Biotech axes revusiran due to safety concerns.
News Alnylam a ‘premier league’ addition to UK biotech UK base will be operational HQ, Switzerland to be official head office
News Alnylam gears up for first RNAi therapeutic filing in 2017 US biotech Alnylam says it could file its first product in 2017, a rare disease drug using what has long promised to be a revolutionary approach, RNA interference.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
